ARCA biopharma, Inc.
ABIO
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.62M | 2.32M | 1.54M | 1.62M | 1.72M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.75M | 2.48M | 1.59M | 1.94M | 1.97M |
| Operating Income | -2.75M | -2.48M | -1.59M | -1.94M | -1.97M |
| Income Before Tax | -2.68M | -2.01M | -1.09M | -1.42M | -1.48M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.68M | -2.01M | -1.09M | -1.42M | -1.48M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.68M | -2.01M | -1.09M | -1.42M | -1.48M |
| EBIT | -2.75M | -2.48M | -1.59M | -1.94M | -1.97M |
| EBITDA | -2.75M | -2.48M | -1.59M | -1.93M | -1.97M |
| EPS Basic | -0.18 | -0.14 | -0.08 | -0.10 | -0.10 |
| Normalized Basic EPS | -0.10 | -0.09 | -0.05 | -0.06 | -0.06 |
| EPS Diluted | -0.18 | -0.14 | -0.08 | -0.10 | -0.10 |
| Normalized Diluted EPS | -0.10 | -0.09 | -0.05 | -0.06 | -0.06 |
| Average Basic Shares Outstanding | 14.51M | 14.50M | 14.43M | 14.41M | 14.41M |
| Average Diluted Shares Outstanding | 14.51M | 14.50M | 14.43M | 14.41M | 14.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
